PLEASANTON, Calif., Aug. 22, 2024 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 10:45 a.m. Eastern Time.
Interested parties may access a live webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
SOURCE 10x Genomics, Inc.
Q2 2024 Revenue Increased 119% Year-over-Year to Over $6.0 Million, Exceeding Management Guidance Management Expects…
The Innovaccer copilot will be deployed on Oracle Cloud Infrastructure to automate clinical documentation, generate…
MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #holx--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at…
MENLO PARK, Calif.--(BUSINESS WIRE)--#FDA--Jupiter Endovascular, Inc., a medical technology startup developing a new class of…
Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDTMarlborough,…
The targeted acquisition is estimated to have a business value of approximately $10 million and…